NateraNTRA
NTRA
About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Employees: 4,434
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
284% more first-time investments, than exits
New positions opened: 142 | Existing positions closed: 37
30% more capital invested
Capital invested by funds: $15.3B [Q3] → $19.8B (+$4.52B) [Q4]
21% more funds holding in top 10
Funds holding in top 10: 24 [Q3] → 29 (+5) [Q4]
20% more funds holding
Funds holding: 488 [Q3] → 584 (+96) [Q4]
4.53% more ownership
Funds ownership: 97.2% [Q3] → 101.72% (+4.53%) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 183 | Existing positions reduced: 205
17% less call options, than puts
Call options by funds: $136M | Put options by funds: $163M
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$185
24%
upside
Avg. target
$205
37%
upside
High target
$251
68%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler David Westenberg 52% 1-year accuracy 24 / 46 met price target | 41%upside $210 | Overweight Maintained | 15 May 2025 |
UBS Elizabeth Garcia 33% 1-year accuracy 1 / 3 met price target | 46%upside $218 | Buy Maintained | 9 May 2025 |
Barclays Luke Sergott 35% 1-year accuracy 22 / 63 met price target | 27%upside $190 | Overweight Maintained | 9 May 2025 |
RBC Capital Conor McNamara 15% 1-year accuracy 6 / 41 met price target | 68%upside $251 | Outperform Initiated | 13 Mar 2025 |
Morgan Stanley Tejas Savant 30% 1-year accuracy 6 / 20 met price target | 24%upside $185 | Overweight Maintained | 5 Mar 2025 |
Financial journalist opinion
Based on 13 articles about NTRA published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
Seeking Alpha
1 week ago
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 week ago
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago.
Neutral
Business Wire
1 week ago
Natera Reports First Quarter 2025 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter o.
Neutral
Business Wire
1 week ago
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025. Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap Healthcare Collaborative, will be shared in a mini-oral presentation on May 16, 2025. The report includes data from 712.
Neutral
Business Wire
1 week ago
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection. Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor fraction (dd-cfDNA %, measuring dd-cfDNA as a fraction of total cfDNA) and donor quantity score (DQS, estimating the to.
Neutral
Business Wire
1 week ago
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study led by Stanford University School of Medicine for the evaluation of Signatera, Natera's personalized molecular residual disease (MRD) test, in patients with soft tissue and bone sarcomas. Results of the study (Utilizing Circulating Tumor DNA to Monitor Sarcoma Treatment and Recurrence) were presented at the 2025 Society of Surgical Oncology.
Neutral
Business Wire
2 weeks ago
Natera to Report its First Quarter Results on May 8, 2025
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2025 Financial Results Date: May 8, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1.
Neutral
Business Wire
2 weeks ago
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced the results of its DEFINE-HT clinical trial in heart transplantation, which were shared today, April 29, 2025, in an oral presentation at the International Society for Heart and Lung Transplantation 45th Annual Meeting in Boston, MA. DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-der.
Positive
Seeking Alpha
2 weeks ago
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.
Charts implemented using Lightweight Charts™